UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Breast cancer research and treatment, 2018-02, Vol.167 (3), p.671-686

2018

Volltextzugriff (PDF)

Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer

Journal of clinical oncology, 2004-12, Vol.22 (23), p.4753-4709

2004

Volltextzugriff (PDF)

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8034-8034

2015

Volltextzugriff (PDF)

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Clinical cancer research, 2013-12, Vol.19 (23), p.6614-6623

2013

Volltextzugriff (PDF)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Annals of oncology, 2016-03, Vol.27 (3), p.417-423

2016

Volltextzugriff (PDF)

Reflections

The oncologist (Dayton, Ohio), 2007-10, Vol.12 (10), p.3012-3014

Gurtler, Jayne

2007

Volltextzugriff (PDF)

Reflections

The oncologist (Dayton, Ohio), 2007-10, Vol.12 (10), p.3012-3014

Gurtler, Jayne

2007

Volltextzugriff (PDF)

Abstract B104: Identifying gaps in equitable cancer care: insights from US-based oncology professionals engaged in continuing medical education

Cancer epidemiology, biomarkers & prevention, 2024-09, Vol.33 (9_Supplement), p.B104-B104

2024

Volltextzugriff (PDF)

Multidisciplinary education and action to foster equitable cancer care

JCO oncology practice, 2023-11, Vol.19 (11_suppl), p.193-193

2023

Volltextzugriff (PDF)

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4134-TPS4134

2016

Volltextzugriff (PDF)

Katrina's Lessons: Out of the Worst Come Some of the Best

The oncologist (Dayton, Ohio), 2005-09, Vol.10 (8), p.661-662

Gurtler, Jayne

2005

Volltextzugriff (PDF)

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Cancer, 2014-06, Vol.120 (11), p.1647-1655

2014

Volltextzugriff (PDF)

P-282JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

Annals of oncology, 2016-06, Vol.27 (Suppl 2), p.ii82-ii82

2016

Volltextzugriff (PDF)

P-282 JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

Annals of oncology, 2016-06, Vol.27, p.ii82

2016

Volltextzugriff (PDF)

P-282JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC plus or minus chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii82-ii82

2016

Volltextzugriff (PDF)

P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer

Annals of oncology, 2016-06, Vol.27, p.ii81

2016

Volltextzugriff (PDF)

P-281JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii81-ii82

2016

Volltextzugriff (PDF)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1597-1606

2012

Volltextzugriff (PDF)

Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT132-CT132

2016

Volltextzugriff (PDF)

Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4135-TPS4135

2016

Volltextzugriff (PDF)

Introduction to the New Section

The oncologist (Dayton, Ohio), 2006-05, Vol.11 (5), p.450-450

2006

Volltextzugriff (PDF)

Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens

Clinical breast cancer, 2014-12, Vol.14 (6), p.396-404

2014

Volltextzugriff (PDF)

Introduction to the new section. When clinical trials are not an option

The oncologist (Dayton, Ohio), 2006-05, Vol.11 (5), p.450-450

2006

Volltextzugriff (PDF)

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3044-3044

2015

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)
Webseiten
(1)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Reflections

Reflections

Abstract B104: Identifying gaps in equitable cancer care: insights from US-based oncology professionals engaged in continuing medical education

Multidisciplinary education and action to foster equitable cancer care

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial

Katrina's Lessons: Out of the Worst Come Some of the Best

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

P-282JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

P-282 JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

P-282JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC plus or minus chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer

P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer

P-281JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial

Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial

Introduction to the New Section

Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens

Introduction to the new section. When clinical trials are not an option

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study

Suchergebnisse filtern